Replimune Stock Based Compensation from 2010 to 2024

REPL Stock

USD 14.08 0.03 0.21%

Replimune Stock Based Compensation yearly trend continues to be quite stable with very little volatility. Stock Based Compensation may rise above about 35.8 M this year. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2017-06-30

Previous Quarter

9.5 M

Current Value

8.7 M

Quarterly Volatility

3.3 M

Covid

Check Replimune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Replimune's main balance sheet or income statement drivers, such as Interest Income of 935.8 K, Depreciation And Amortization of 2 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.44. Replimune financial statements analysis is a perfect complement when working with Replimune Valuation or Volatility modules.

Check out the analysis of Replimune Correlation against competitors.

Latest Replimune's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Replimune Group over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Replimune's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Replimune's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Replimune Stock Based Compensation Regression Statistics

	Arithmetic Mean	9,791,350
	Geometric Mean	1,699,228
	Coefficient Of Variation	139.11
	Mean Deviation	11,356,600
	Median	812,000
	Standard Deviation	13,620,594
	Sample Variance	185.5T
	Range	35.6M
	R-Value	0.87
	Mean Square Error	48.9T
	R-Squared	0.76
	Significance	0.000026
	Slope	2,646,421
	Total Sum of Squares	2597.3T

Replimune Stock Based Compensation History

	2024	35.8 M
	2023	34.1 M
	2022	28.1 M
	2021	24.3 M
	2020	11.8 M
	2019	7.7 M
	2018	2.7 M

Other Fundumenentals of Replimune Group

Stock Based Compensation To Revenue

Replimune Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Long Term Debt	Long Term Debt Total	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt
Total Assets		0.99	0.95	-0.6	-0.8	0.64	0.81	0.94	0.59	1.0	0.96	0.76	1.0	0.99	0.9	0.92	-0.33	0.92	0.77	0.75
Total Stockholder Equity	0.99		0.95	-0.64	-0.76	0.65	0.78	0.94	0.5	0.99	0.95	0.74	0.99	0.99	0.88	0.91	-0.29	0.89	0.72	0.74
Net Tangible Assets	0.95	0.95		-0.47	-0.87	0.61	0.85	0.99	0.53	0.94	0.94	0.8	0.95	0.94	0.92	0.89	-0.55	0.92	0.77	0.86
Net Debt	-0.6	-0.64	-0.47		0.06	-0.22	-0.14	-0.4	0.01	-0.6	-0.42	-0.01	-0.62	-0.62	-0.37	-0.47	-0.34	-0.32	-0.05	-0.35
Retained Earnings	-0.8	-0.76	-0.87	0.06		-0.49	-0.85	-0.91	-0.73	-0.8	-0.83	-0.87	-0.81	-0.81	-0.9	-0.75	0.77	-0.95	-0.94	-0.76
Accounts Payable	0.64	0.65	0.61	-0.22	-0.49		0.61	0.6	0.26	0.63	0.73	0.61	0.6	0.59	0.41	0.5	-0.21	0.49	0.4	0.29
Net Receivables	0.81	0.78	0.85	-0.14	-0.85	0.61		0.86	0.74	0.8	0.9	0.83	0.78	0.76	0.89	0.85	-0.53	0.87	0.83	0.79
Capital Surpluse	0.94	0.94	0.99	-0.4	-0.91	0.6	0.86		0.58	0.94	0.94	0.84	0.95	0.94	0.93	0.89	-0.59	0.94	0.81	0.86
Total Liab	0.59	0.5	0.53	0.01	-0.73	0.26	0.74	0.58		0.6	0.56	0.61	0.57	0.57	0.7	0.59	-0.44	0.74	0.8	0.47
Total Current Assets	1.0	0.99	0.94	-0.6	-0.8	0.63	0.8	0.94	0.6		0.95	0.74	1.0	1.0	0.9	0.9	-0.32	0.93	0.77	0.74
Common Stock	0.96	0.95	0.94	-0.42	-0.83	0.73	0.9	0.94	0.56	0.95		0.85	0.94	0.93	0.89	0.93	-0.4	0.91	0.79	0.75
Property Plant Equipment	0.76	0.74	0.8	-0.01	-0.87	0.61	0.83	0.84	0.61	0.74	0.85		0.74	0.73	0.75	0.83	-0.6	0.82	0.77	0.62
Net Invested Capital	1.0	0.99	0.95	-0.62	-0.81	0.6	0.78	0.95	0.57	1.0	0.94	0.74		1.0	0.9	0.9	-0.35	0.93	0.76	0.75
Net Working Capital	0.99	0.99	0.94	-0.62	-0.81	0.59	0.76	0.94	0.57	1.0	0.93	0.73	1.0		0.9	0.88	-0.35	0.93	0.77	0.74
Long Term Debt	0.9	0.88	0.92	-0.37	-0.9	0.41	0.89	0.93	0.7	0.9	0.89	0.75	0.9	0.9		0.87	-0.5	0.97	0.91	0.9
Long Term Debt Total	0.92	0.91	0.89	-0.47	-0.75	0.5	0.85	0.89	0.59	0.9	0.93	0.83	0.9	0.88	0.87		-0.3	0.87	0.72	0.75
Deferred Long Term Liab	-0.33	-0.29	-0.55	-0.34	0.77	-0.21	-0.53	-0.59	-0.44	-0.32	-0.4	-0.6	-0.35	-0.35	-0.5	-0.3		-0.56	-0.6	-0.55
Capital Stock	0.92	0.89	0.92	-0.32	-0.95	0.49	0.87	0.94	0.74	0.93	0.91	0.82	0.93	0.93	0.97	0.87	-0.56		0.94	0.79
Current Deferred Revenue	0.77	0.72	0.77	-0.05	-0.94	0.4	0.83	0.81	0.8	0.77	0.79	0.77	0.76	0.77	0.91	0.72	-0.6	0.94		0.69
Short Term Debt	0.75	0.74	0.86	-0.35	-0.76	0.29	0.79	0.86	0.47	0.74	0.75	0.62	0.75	0.74	0.9	0.75	-0.55	0.79	0.69

Click cells to compare fundamentals

About Replimune Financial Statements

Replimune investors utilize fundamental indicators, such as Stock Based Compensation, to predict how Replimune Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

		Last Reported	Projected for Next Year
	Stock Based Compensation	34.1 M	35.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:

How To Invest In Replimune

Details

Is Replimune Stock a good investment?

Details

What is Replimune's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Replimune Correlation against competitors.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.04)

Return On Assets

(0.27)

Return On Equity

(0.50)

The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Replimune Stock Based Compensation from 2010 to 2024

Latest Replimune's Stock Based Compensation Growth Pattern

Replimune Stock Based Compensation Regression Statistics

Replimune Stock Based Compensation History

Other Fundumenentals of Replimune Group

Replimune Stock Based Compensation component correlations

About Replimune Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY